Fatty Liver Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MetS and fatty liver disease been associated with changes in adiponectin, soluble ST2 (sST2), chitinase 3-like 1 (Chi3L1), hyaluronic acid (HA), tissue inhibitor of metalloproteinase-1 (TIMP-1), lysyl oxidase-like-2 (LOXL2) and transforming growth factor β (TGF-β) concentrations in HIV-uninfected populations.
|
29746485 |
2018 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results showed the protective role of Ang-(1-7) in the development of NASH through an adiponectin-independent mechanism, which may be partially attributed to the activation of hepatic AMP-activated protein kinase pathway.
|
26992300 |
2017 |
Fatty Liver Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequencies of adiponectin gene promoter-11377C/G(CG), -11377C/G (GG), GPx-1 gene C594T (CT) and C594T (TT) were 24.50%, 26.00%, 24.00%, and 25.50% in the NAFL group, 34.50%, 37.00%, 35.00%, and 36.00% in the NASH group, 42.00%, 46.00%, 43.50%, and 45.50% in the NAFHC group, and 14.00%, 14.50%, 13.00%, and 14.00% in the control group, respectively.
|
26897098 |
2016 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Human liver PPARα gene expression negatively correlates with NASH severity, visceral adiposity and insulin resistance and positively with adiponectin.
|
25703085 |
2015 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Adiponectin levels increased continuously in NASH patients, whereas NAFL patients plateaued at 4 weeks post-operatively.
|
23627434 |
2013 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The p.148 M PNPLA3 variant was associated with decreased adiponectin mRNA levels in the VAT of obese patients (p < 0.05) even in the absence of NASH.
|
22898488 |
2012 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The current data indicate that in NASH hepatic inflammation and fibrosis but not hepatic steatosis induce liver MMP-9 activity, and this induction seems to be related to the anti-inflammatory activity of adiponectin rather than its effect on hepatocellular MMP-9 expression.
|
21791204 |
2011 |
Fatty Liver Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Variations in adiponectin levels could be an indicator of disease progression since inflammatory infiltrates are commonly associated with nonalcoholic steatohepatitis (NASH) in morbidly obese patients.
|
20041267 |
2010 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with NASH had significantly higher mRNA adiponectin levels and lower IL-6 levels than did those with a normal liver (P<0.05).
|
18376369 |
2008 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Also, adiponectin levels were compared with those of a control group of 30 healthy volunteers with normal ultrasound findings of the upper abdomen who had no known NASH risk factors.
|
18029322 |
2008 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prevalence of adiponectin single-nucleotide polymorphisms (SNPs) 45GT and 276GT was assessed in 70 nonobese, nondiabetic, normolipidemic NAFLD patients and 70 healthy matched controls; the impact of the adiponectin SNPs was subsequently correlated to liver histology and postprandial adiponectin and lipoprotein responses to oral fat load in a subgroup of 30 biopsy-proven patients with NASH and 30 controls.
|
18311774 |
2008 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adiponectin and its receptors in rodent models of fatty liver disease and liver cirrhosis.
|
17006986 |
2006 |
Fatty Liver Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum adiponectin level was the only predictor of nonalcoholic steatohepatitis (NASH) in this study (P=0.024).
|
16989692 |
2006 |
Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adiponectin and adipoRII staining were lower in biopsies of subjects with NASH compared with simple steatosis.
|
15591515 |
2005 |